USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

Yuning Liao, Ningning Liu, Xiaohong Xia, Zhiqiang Guo, Yanling Li, Lili Jiang, Ruiqing Zhou, Daolin Tang, Hongbiao Huang, Jinbao Liu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for CML patients. However, acquired resistance to TKIs that develops overtime in the long-term administration renders TKIs ineffective to patients with advanced CML. Therefore, increasing studies focus on the amplified expression or activation of Bcr-Abl which is proposed to contribute to the advanced phase. Here, we show that S-phase kinase-associated protein 2 (SKP2) acts as a co-regulator of Bcr-Abl by mediating its K63-linked ubiquitination and activation. Further investigations show that USP10 as a novel deubiquitinase of SKP2 amplifies the activation of Bcr-Abl via mediating deubiquitination and stabilization of SKP2 in CML cells. Moreover, inhibition of USP10 significantly suppresses the proliferation of both imatinib-sensitive and imatinib-resistant CML cells, which likely depends on SKP2 status. This findings are confirmed in primary CML cells because these cells are over-expressed with USP10 and SKP2 and are sensitive to a USP10 inhibitor. Taken together, the present study not only provides a novel insight into the amplified activation of Bcr-Abl in CML, but also demonstrates that targeting the USP10/SKP2/Bcr-Abl axis is a potential strategy to overcome imatinib resistance in CML patients.

Original languageEnglish (US)
Article number24
JournalCell Discovery
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

S-Phase Kinase-Associated Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chemical activation
Protein-Tyrosine Kinases
Myeloid Cells
bcr-abl Fusion Proteins
Ubiquitination
Stabilization

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this

USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. / Liao, Yuning; Liu, Ningning; Xia, Xiaohong; Guo, Zhiqiang; Li, Yanling; Jiang, Lili; Zhou, Ruiqing; Tang, Daolin; Huang, Hongbiao; Liu, Jinbao.

In: Cell Discovery, Vol. 5, No. 1, 24, 01.12.2019.

Research output: Contribution to journalArticle

Liao, Y, Liu, N, Xia, X, Guo, Z, Li, Y, Jiang, L, Zhou, R, Tang, D, Huang, H & Liu, J 2019, 'USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia', Cell Discovery, vol. 5, no. 1, 24. https://doi.org/10.1038/s41421-019-0092-z
Liao, Yuning ; Liu, Ningning ; Xia, Xiaohong ; Guo, Zhiqiang ; Li, Yanling ; Jiang, Lili ; Zhou, Ruiqing ; Tang, Daolin ; Huang, Hongbiao ; Liu, Jinbao. / USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. In: Cell Discovery. 2019 ; Vol. 5, No. 1.
@article{01874cba545346e6903b7bf8b11236ee,
title = "USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia",
abstract = "Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for CML patients. However, acquired resistance to TKIs that develops overtime in the long-term administration renders TKIs ineffective to patients with advanced CML. Therefore, increasing studies focus on the amplified expression or activation of Bcr-Abl which is proposed to contribute to the advanced phase. Here, we show that S-phase kinase-associated protein 2 (SKP2) acts as a co-regulator of Bcr-Abl by mediating its K63-linked ubiquitination and activation. Further investigations show that USP10 as a novel deubiquitinase of SKP2 amplifies the activation of Bcr-Abl via mediating deubiquitination and stabilization of SKP2 in CML cells. Moreover, inhibition of USP10 significantly suppresses the proliferation of both imatinib-sensitive and imatinib-resistant CML cells, which likely depends on SKP2 status. This findings are confirmed in primary CML cells because these cells are over-expressed with USP10 and SKP2 and are sensitive to a USP10 inhibitor. Taken together, the present study not only provides a novel insight into the amplified activation of Bcr-Abl in CML, but also demonstrates that targeting the USP10/SKP2/Bcr-Abl axis is a potential strategy to overcome imatinib resistance in CML patients.",
author = "Yuning Liao and Ningning Liu and Xiaohong Xia and Zhiqiang Guo and Yanling Li and Lili Jiang and Ruiqing Zhou and Daolin Tang and Hongbiao Huang and Jinbao Liu",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41421-019-0092-z",
language = "English (US)",
volume = "5",
journal = "Cell Discovery",
issn = "2056-5968",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

AU - Liao, Yuning

AU - Liu, Ningning

AU - Xia, Xiaohong

AU - Guo, Zhiqiang

AU - Li, Yanling

AU - Jiang, Lili

AU - Zhou, Ruiqing

AU - Tang, Daolin

AU - Huang, Hongbiao

AU - Liu, Jinbao

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for CML patients. However, acquired resistance to TKIs that develops overtime in the long-term administration renders TKIs ineffective to patients with advanced CML. Therefore, increasing studies focus on the amplified expression or activation of Bcr-Abl which is proposed to contribute to the advanced phase. Here, we show that S-phase kinase-associated protein 2 (SKP2) acts as a co-regulator of Bcr-Abl by mediating its K63-linked ubiquitination and activation. Further investigations show that USP10 as a novel deubiquitinase of SKP2 amplifies the activation of Bcr-Abl via mediating deubiquitination and stabilization of SKP2 in CML cells. Moreover, inhibition of USP10 significantly suppresses the proliferation of both imatinib-sensitive and imatinib-resistant CML cells, which likely depends on SKP2 status. This findings are confirmed in primary CML cells because these cells are over-expressed with USP10 and SKP2 and are sensitive to a USP10 inhibitor. Taken together, the present study not only provides a novel insight into the amplified activation of Bcr-Abl in CML, but also demonstrates that targeting the USP10/SKP2/Bcr-Abl axis is a potential strategy to overcome imatinib resistance in CML patients.

AB - Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for CML patients. However, acquired resistance to TKIs that develops overtime in the long-term administration renders TKIs ineffective to patients with advanced CML. Therefore, increasing studies focus on the amplified expression or activation of Bcr-Abl which is proposed to contribute to the advanced phase. Here, we show that S-phase kinase-associated protein 2 (SKP2) acts as a co-regulator of Bcr-Abl by mediating its K63-linked ubiquitination and activation. Further investigations show that USP10 as a novel deubiquitinase of SKP2 amplifies the activation of Bcr-Abl via mediating deubiquitination and stabilization of SKP2 in CML cells. Moreover, inhibition of USP10 significantly suppresses the proliferation of both imatinib-sensitive and imatinib-resistant CML cells, which likely depends on SKP2 status. This findings are confirmed in primary CML cells because these cells are over-expressed with USP10 and SKP2 and are sensitive to a USP10 inhibitor. Taken together, the present study not only provides a novel insight into the amplified activation of Bcr-Abl in CML, but also demonstrates that targeting the USP10/SKP2/Bcr-Abl axis is a potential strategy to overcome imatinib resistance in CML patients.

UR - http://www.scopus.com/inward/record.url?scp=85065062376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065062376&partnerID=8YFLogxK

U2 - 10.1038/s41421-019-0092-z

DO - 10.1038/s41421-019-0092-z

M3 - Article

C2 - 31044085

AN - SCOPUS:85065062376

VL - 5

JO - Cell Discovery

JF - Cell Discovery

SN - 2056-5968

IS - 1

M1 - 24

ER -